Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30331782 | 1.00 | PARP1 (0.84) | PARP1PARP3 | |
| SCHEMBL30293115 | 0.97 | PARP1 (0.89) | PARP1PARP3 | |
| SCHEMBL19569971 | 0.95 | PARP1 (0.90) | PARP1PARP3 | |
| SCHEMBL30331719 | 0.93 | PARP1 (0.80) | PARP1PARP3 | |
| SCHEMBL30436447 | 0.92 | PARP1 (0.82) | PARP1PARP3 | |
| SCHEMBL16571973 | 0.92 | PARP1 (0.82) | PARP1PARP3 | |
| SCHEMBL29434944 | 0.91 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL864319 | 0.91 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL30205023 | 0.91 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL524782 | 0.91 | PARP1 (1.00) | PARP1PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11542282-B2 | Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200407374-A1 | LOW AFFINITY POLY(AD-RIBOSE) POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-31 | — | — | US | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| CN-108727338-A | A kind of 4- piperidines ketone compounds and the preparation method and application thereof | 福建医科大学 | 2018-11-02 | — | — | CN | disclosed |
| US-20180057464-A1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN, LTD. (TW) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542282-B2 | Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents | PARP1, PARP11, PARP2 | PARP1 1/4885PARP3 6/4885 |
| US-20180057464-A1 | PROCESSES FOR PREPARING OLAPARIB | PARP1, PARP2, PARP3 | PARP1 1/4885PARP3 3/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PARP3 1005/4885 |
| US-20200407374-A1 | LOW AFFINITY POLY(AD-RIBOSE) POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS | PARP1, PARP11, PARP2 | PARP1 1/4885PARP3 6/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PARP3 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.